IHL 0.00% 4.1¢ incannex healthcare limited

I was looking at AXIM’s clinical development pipeline and see...

  1. 321 Posts.
    lightbulb Created with Sketch. 739
    I was looking at AXIM’s clinical development pipeline and see that they are up to phase 2 in their cannabinoid product for psoriasis and dermatitis. It’s called AX1602.

    Interestingly Botanix has a similar cream in development at the same phase. It made me wonder who has the better business model?

    By collaborating with AXIM, IHL gets access to new products for sale while the rest of the market spends millions upon millions on R & D before they even get approval let alone begin to generate revenue.

    It’s dawnwed on me what IHL are doing now. It also means that IHL should be well poised for uplift as regulations loosen without the massive spend and dilution.

    Ted
 
watchlist Created with Sketch. Add IHL (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.